Trial Profile
A randomised, controlled, comparative, open-label, multicenter study on the safety and efficacy of Neutrogen and Neupogen in prevention of chemotherapy-induced neutropenia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Virchow Group
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.
- 22 Jun 2018 New trial record